… This article reviews data from: PIONEER 6, a phase 3a cardiovascular outcomes trial in …
that will evaluate subcutaneous semaglutide in patients with established CVD and obesity, but …

… There is no pre-specified duration of exposure to trial medication and so it is likely that there
… than seen in the similar CV outcome trials for liraglutide and sc semaglutide.22, 23 Follow-…

… semaglutide, the first GLP-1-based drug, for the reduction of the risk of serious heart problems
in adults with obesity. … be another mechanism driving improved cardiovascular outcomes? …

… Duration of intervention in most trials ranged from 12 to 56 weeks, with the exception of
the SUSTAIN-6 trial, a dedicated cardiovascular outcomes study,9 that had a duration of 104 …

… Effect of weekly subcutaneous Semaglutide vs. daily liraglutide on body weight in adults
with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;…

… semaglutide. The purpose of this review was to provide an analysis of … semaglutide as a
pharmacotherapeutic option for obesity. … The Semaglutide Effects on cardiovascular Outcomes in …

… Semaglutide in Subjects with Type 2 Diabetes) was a pre-licensing FDA-mandated
cardiovascular outcome trial with subcutaneous semaglutide … subjects with overweight or obesity. …

… semaglutide is efficacious for sustained weight loss among individuals with overweight/obesity
and without diabetes. … Semaglutide and Cardiovascular Outcomes in Patients with Type 2 …

… obesity [(10)], leading to its approval for the treatment of obesity in individuals with or without
diabetes … However, the efficacy of semaglutide in patients with a body mass index (BMI) ≥ …

… aimed to provide a more definitive assessment of the effects of semaglutide across a range
of outcomes and to test whether these effects were consistent across key patient subgroups. …